CD200 is induced by ERK and is a potential therapeutic target in melanoma
Open Access
- 15 November 2007
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 117 (12), 3922-3929
- https://doi.org/10.1172/jci32163
Abstract
Immune-mediated antitumor responses occur in patients with metastatic melanoma (MM), and therapies designed to augment such responses are clinically beneficial. Despite the immunogenicity of melanoma, immunomodulatory therapies fail in the majority of patients with MM. An inability of DCs to sufficiently activate effector cells may, in part, underlie this failure of the antitumor response seen in most patients. In this work, we show that mutation of N-RAS or B-RAF, signature genetic lesions present in most MMs, potently induced the expression of cell-surface CD200, a repressor of DC function. Employing 2 independent, genome-wide microarray analyses, we identified CD200 as a highly dynamic, downstream target of RAS/RAF/MEK/ERK activation in melanoma. CD200 protein was similarly overexpressed in human melanoma cell lines and primary tumors. CD200 mRNA expression correlated with progression and was higher in melanoma than in other solid tumors or acute leukemia. Melanoma cell lines expressing endogenous CD200 repressed primary T cell activation by DCs, while knockdown of CD200 by shRNA abrogated this immunosuppressive effect. These data indicate that in addition to its effects on growth, survival, and motility, ERK activation in MM attenuates a host antitumor immune response, implicating CD200 and its interaction with the CD200 receptor as a potential therapeutic target for MM.Keywords
This publication has 48 references indexed in Scilit:
- CD200 as a prognostic factor in acute myeloid leukaemiaLeukemia, 2007
- Therapeutic implications of autoimmune vitiligo T cellsAutoimmunity Reviews, 2006
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Management of Metastatic Melanoma 2005Surgical Oncology Clinics of North America, 2006
- Strategies for the Development of More Effective Adjuvant Therapy of Melanoma: Current and Future Explorations of Antibodies, Cytokines, Vaccines, and CombinationsClinical Cancer Research, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- The English strain of rat cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and a spliced CC chemokine upstream from the major immediate-early region: further evidence for a separate evolutionary lineage from that of rat CMV MaastrichtJournal of General Virology, 2005
- Human Herpesvirus 8 K14 Protein Mimics CD200 in Down-Regulating Macrophage Activation through CD200 ReceptorJournal of Virology, 2004
- Systematic variation in gene expression patterns in human cancer cell linesNature Genetics, 2000
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983